radiprodil
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2009 (NCT00838799)
Timeline
Indications
Mechanism of action
- Glutamate NMDA receptor; GRIN1/GRIN2BANTAGONIST
Glutamate NMDA receptor; GRIN1/GRIN2B antagonist
Non-competitive antagonist, negative modulator.
GRIN2B selective.
Binds to ifenprodil site on N-terminal domain.
Chemistry & pharmacology
Loading structure…
SMILES
O=C(Nc1ccc2nc(O)oc2c1)C(=O)N1CCC(Cc2ccc(F)cc2)CC1- Mol. weight
- 397.41 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL182066 ↗
Also known as
- radiprodil
- radiprodil
- radiprodil
- radiprodil
- rgh-896
- rgh-896
- rgh-896
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02829827 | Phase 2 | Jul 1, 2017 | Hoosier Cancer Research Network |
| NCT02647697 | Phase 1 | Jan 1, 2016 | Hoosier Cancer Research Network, Pharmaceutical Research Associates, Inc. (PRA) |
| NCT00838799 | Phase 2 | Feb 1, 2009 | Forest Laboratories, Gedeon Richter Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hoosier Cancer Research Network | Academic/Hospital | 2 | 2 | 2 | 2016 |
| Forest Laboratories | For profit | 1 | 1 | 1 | 2009 |
| Gedeon Richter Ltd. | For profit | 1 | 0 | 1 | 2009 |
| Pharmaceutical Research Associates, Inc. (PRA) | For profit | 1 | 0 | 1 | 2016 |
4 organizations
Page 1 / 1